Bank of America Corporation reissued their buy rating on shares of Abbott Laboratories (NYSE:ABT) in a research report sent to investors on Wednesday morning. They currently have a $60.00 price objective on the healthcare product maker’s stock, up from their prior price objective of $56.00.

Several other brokerages have also recently commented on ABT. TheStreet raised Abbott Laboratories from a c+ rating to a b rating in a report on Monday, July 3rd. BidaskClub cut Abbott Laboratories from a strong-buy rating to a buy rating in a report on Monday, July 31st. Stifel Nicolaus reissued a buy rating and set a $58.00 target price on shares of Abbott Laboratories in a report on Friday, July 21st. Jefferies Group LLC reissued a buy rating and set a $58.00 target price on shares of Abbott Laboratories in a report on Thursday, June 29th. Finally, Guggenheim assumed coverage on Abbott Laboratories in a report on Thursday, June 29th. They set a buy rating and a $58.00 target price on the stock. Eight investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $54.75.

Shares of Abbott Laboratories (NYSE ABT) opened at 55.00 on Wednesday. Abbott Laboratories has a 12-month low of $37.38 and a 12-month high of $55.11. The stock has a 50 day moving average price of $51.71 and a 200 day moving average price of $47.76. The stock has a market capitalization of $95.56 billion, a P/E ratio of 77.03 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.60 by $0.02. The firm had revenue of $6.64 billion for the quarter, compared to analysts’ expectations of $6.63 billion. Abbott Laboratories had a net margin of 4.96% and a return on equity of 14.43%. Abbott Laboratories’s revenue was up 24.5% on a year-over-year basis. During the same quarter last year, the company posted $0.55 earnings per share. On average, equities analysts anticipate that Abbott Laboratories will post $2.49 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/abbott-laboratories-abt-buy-rating-reiterated-at-bank-of-america-corporation/1616949.html.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be issued a dividend of $0.265 per share. The ex-dividend date is Thursday, October 12th. This represents a $1.06 annualized dividend and a dividend yield of 1.93%. Abbott Laboratories’s payout ratio is 149.30%.

In related news, insider Brian J. Blaser sold 15,000 shares of the company’s stock in a transaction dated Thursday, July 27th. The shares were sold at an average price of $50.00, for a total value of $750,000.00. Following the sale, the insider now owns 143,154 shares of the company’s stock, valued at $7,157,700. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Daniel Gesua Sive Salvadori sold 62,460 shares of the company’s stock in a transaction dated Tuesday, September 26th. The shares were sold at an average price of $52.95, for a total transaction of $3,307,257.00. Following the completion of the sale, the insider now directly owns 113,426 shares in the company, valued at approximately $6,005,906.70. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 333,310 shares of company stock worth $16,857,255. Insiders own 0.76% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Abbott Laboratories by 2.6% in the second quarter. Vanguard Group Inc. now owns 129,786,955 shares of the healthcare product maker’s stock valued at $6,308,944,000 after acquiring an additional 3,241,063 shares during the period. State Street Corp increased its stake in Abbott Laboratories by 18.9% in the first quarter. State Street Corp now owns 80,499,469 shares of the healthcare product maker’s stock valued at $3,574,987,000 after acquiring an additional 12,806,535 shares during the period. Capital Research Global Investors increased its stake in Abbott Laboratories by 45.7% in the second quarter. Capital Research Global Investors now owns 47,589,663 shares of the healthcare product maker’s stock valued at $2,313,334,000 after acquiring an additional 14,918,038 shares during the period. Bank of New York Mellon Corp increased its stake in Abbott Laboratories by 11.0% in the first quarter. Bank of New York Mellon Corp now owns 33,796,869 shares of the healthcare product maker’s stock valued at $1,500,920,000 after acquiring an additional 3,344,508 shares during the period. Finally, Northern Trust Corp increased its stake in Abbott Laboratories by 3.1% in the second quarter. Northern Trust Corp now owns 26,865,706 shares of the healthcare product maker’s stock valued at $1,305,942,000 after acquiring an additional 809,732 shares during the period. 71.50% of the stock is currently owned by institutional investors and hedge funds.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Analyst Recommendations for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.